Last reviewed · How we verify
Glibenclamide 5 mg
Glibenclamide 5 mg, developed by the University of Campinas, Brazil, is a marketed drug with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence and long-term use for its primary indication. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | Glibenclamide 5 mg |
|---|---|
| Also known as | Daonil, Glyburide |
| Sponsor | University of Campinas, Brazil |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Diabetes Management for Primary Healthcare Centers. (NA)
- A Study to Evaluate the Efficacy and Safety of BIIB093 in Participants With Brain Contusion (PHASE2)
- Durability of Combination Therapy With Exenatide/Pioglitazone/Metformin vs. Conventional Therapy in New Onset T2DM (PHASE4)
- Glyburide/Metformin 5 mg/500 mg Film-Coated Tablets, Fed (PHASE1)
- Glyburide/Metformin 5 mg/500 mg Film-Coated Tablets, Fasting (PHASE1)
- Safety and Efficacy of Glibenclamide Combined With Rt-PA in Acute Cerebral Embolism (PHASE2, PHASE3)
- Assessment of Dapagliflozin Effect on Diabetic Endothelial Dysfunction of Brachial Artery (PHASE4)
- Study to Evaluate the Effect of IW-3718 on the Pharmacokinetics of Oral Contraceptive, Levothyroxine, Glyburide, and Digoxin in Healthy Adult Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Glibenclamide 5 mg CI brief — competitive landscape report
- Glibenclamide 5 mg updates RSS · CI watch RSS
- University of Campinas, Brazil portfolio CI